Posts

Blind cavefish have extraordinary taste buds

Over thousands of years, cavefish evolved and lost their vision, earning the mon...

APS PRESS publishes the first book devoted specifically...

For greenhouse producers worldwide, the western flower thrips (Frankliniella occ...

Low oxygen and weight status trial seeking participants...

Can reduced oxygen in the air lead to weight loss? That is what Pennington Biome...

It’s a rave – underground acoustics amplify soil health

Barely audible to human ears, healthy soils produce a cacophony of sounds in man...

Pfizer Releases ABRYSVO for RSV: Top-Line Results in Im...

Pfizer reported top-line interim safety and immunogenicity outcomes from Substud...

US FDA Rejects Lykos’ MDMA-Based PTSD Therapy

Lykos Therapeutics said that the U.S. Food and Drug Administration (FDA) has rej...

Acelyrin deprioritises lead therapy despite Phase III w...

As part of pipeline reprioritisation, Acelyrin has dropped izokibep and will ins...

Diabesity: Overlapping pathophysiology informs multi-in...

In 2021, the Centers for Disease Control and Prevention estimated that 49 percen...

NorthStar and Convergent expand deal for prostate cance...

NorthStar Medical Radioisotopes and Convergent Therapeutics have announced an ex...

UAE approves BioArctic and Eisai’s Leqembi for Alzheime...

The Ministry of Health and Prevention in the UAE has granted approval for BioArc...

China approves AstraZeneca-Daiichi Sankyo’s gastric can...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), has received ...

Eli Lilly inaugurates R&D facility in Boston, US

Eli Lilly and Company has opened the Lilly Seaport Innovation Center (LSC), an R...

US judge denies initial attempt by Novartis to block ge...

The court rebuffed claims by Novartis that it would experience “irreparable harm...

Replimune kickstarts Phase III melanoma trial studying ...

IGNYTE-3 is a Phase III trial investigating Replimune’s flagship oncolytic treat...

Kezar stalls solid tumour trial to focus on autoimmune ...

Kezar plans to focus all efforts on zetomipzomib, which is being evaluated in tw...

Bavarian Nordic outlays 215,000 mpox vaccine dose suppl...

Africa CDC’s director general Dr. Jean Kaseya stated the number of rising mpox c...